Revisiting Freund's incomplete adjuvant for vaccines in the developing world.
The rightful emphasis on collaboration between the public and private sectors in solving the world's health problems, especially those of the poor in the developing world, relies on industry developing new technologies with the support of government and foundations. However, certain products, despite their potential to have a great impact on disease in the developing world, will not be developed by industry because they carry the risk of lawsuits owing to possible severe adverse reactions--risks that are not counterbalanced by potential profit of products that are of limited use in the developed world. Freund's incomplete adjuvant (FIA) is one such example that is better developed in the public sector. In this article, we present the evidence that has led to our interest in FIA, evidence of its potential benefit in vaccines against blood-stage malaria, and the way forward to make safe, effective and affordable vaccines for malaria and other serious diseases in the developing world.
Miller
Louis H
LH
Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Twinbrook 1, 5640 Fishers Lane, Rockville, MD 20818, USA.
Saul
Allan
A
Mahanty
Siddhartha
S
D000818:Animals; D003906:Developing Countries; D005620:Freund's Adjuvant / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008288:Malaria / Q000517:prevention & control*; D017780:Malaria Vaccines / Q000592:standards*
D017780:Malaria Vaccines; D005620:Freund's Adjuvant